Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
The Motley Fool
Johnson & Johnson announced plans to acquire Intra-Cellular Therapies for $14.6 billion, which could bolster its pipeline and strengthen its neurological business. However, the acquisition is unlikely to turn Johnson & Johnson into a high-growth stock, as its growth rate is expected to remain in the single digits.
Continue Reading